AstraZeneca Pharma India Limited

NSEI:ASTRAZEN Rapport sur les actions

Capitalisation boursière : ₹187.9b

AstraZeneca Pharma India Résultats passés

Passé contrôle des critères 1/6

AstraZeneca Pharma India a connu une croissance annuelle moyenne de ses bénéfices de 15.2%, tandis que le secteur Pharmaceuticals a vu ses bénéfices augmenter de en hausse à 13.9% par an. Les revenus ont augmenté de en hausse à un taux moyen de 10.6% par an. Le rendement des capitaux propres de AstraZeneca Pharma India est 13.5% et ses marges nettes sont de 6.9%.

Informations clés

15.2%

Taux de croissance des bénéfices

15.2%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie17.5%
Taux de croissance des recettes10.6%
Rendement des fonds propres13.5%
Marge nette6.9%
Prochaine mise à jour des résultats13 Nov 2024

Mises à jour récentes des performances passées

We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Jun 03
We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Recent updates

AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors

Sep 18
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Earnings Haven't Escaped The Attention Of Investors

We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Jun 03
We Believe AstraZeneca Pharma India's (NSE:ASTRAZEN) Earnings Are A Poor Guide For Its Profitability

Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S

May 22
Why Investors Shouldn't Be Surprised By AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) P/S

We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease

Apr 04
We Ran A Stock Scan For Earnings Growth And AstraZeneca Pharma India (NSE:ASTRAZEN) Passed With Ease

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Nov 10
Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00

Jul 06
AstraZeneca Pharma India's (NSE:ASTRAZEN) Dividend Will Be Increased To ₹16.00

Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Jun 16
Is Now The Time To Put AstraZeneca Pharma India (NSE:ASTRAZEN) On Your Watchlist?

Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Aug 02
Increases to CEO Compensation Might Be Put On Hold For Now at AstraZeneca Pharma India Limited (NSE:ASTRAZEN)

Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock

Feb 25
Here's Why I Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is An Interesting Stock

Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Feb 04
Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Jan 18
Declining Stock and Solid Fundamentals: Is The Market Wrong About AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years

Dec 31
Announcing: AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Increased An Energizing 282% In The Last Five Years

We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability

Dec 13
We're Not Counting On AstraZeneca Pharma India (NSE:ASTRAZEN) To Sustain Its Statutory Profitability

Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching

Nov 25
Here's Why We Think AstraZeneca Pharma India (NSE:ASTRAZEN) Is Well Worth Watching

Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay

Nov 07
Here's What We Think About AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Pay

What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

Oct 20
What Kind Of Investors Own Most Of AstraZeneca Pharma India Limited (NSE:ASTRAZEN)?

AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Sep 24
AstraZeneca Pharma India Limited's (NSE:ASTRAZEN) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today

Aug 28
If You Had Bought AstraZeneca Pharma India (NSE:ASTRAZEN) Stock Three Years Ago, You Could Pocket A 298% Gain Today

What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?

Aug 02
What Did AstraZeneca Pharma India's (NSE:ASTRAZEN) CEO Take Home Last Year?

Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Jul 12
Could The AstraZeneca Pharma India Limited (NSE:ASTRAZEN) Ownership Structure Tell Us Something Useful?

Ventilation des recettes et des dépenses

Comment AstraZeneca Pharma India gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

NSEI:ASTRAZEN Recettes, dépenses et bénéfices (INR Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 2413,8769592,4960
31 Mar 2412,9551,6152,4740
31 Dec 2311,9701,3932,7090
30 Sep 2311,4101,5282,6330
30 Jun 2310,6611,3302,5670
31 Mar 2310,0309932,6080
31 Dec 229,5021,1002,6470
30 Sep 229,0099212,5520
30 Jun 228,6257152,4830
31 Mar 228,0566162,3450
31 Dec 217,8396092,2790
30 Sep 217,8367052,2310
30 Jun 217,9548492,2360
31 Mar 218,1369332,2270
31 Dec 207,9827562,2450
30 Sep 208,2188132,1960
30 Jun 208,2086932,1760
31 Mar 208,3187222,1960
31 Dec 198,2727252,0700
30 Sep 198,1857492,1040
30 Jun 197,7146961,9980
31 Mar 197,2835452,0610
31 Dec 186,8874781,9560
30 Sep 186,021831,8870
30 Jun 186,0502651,8370
31 Mar 185,7102591,5570
31 Dec 175,3191751,4930
30 Sep 175,5364421,4390
30 Jun 175,2751762,1050
31 Mar 175,4372011,5870
31 Dec 165,8662791,8180
30 Sep 165,8092061,7770
30 Jun 165,7111311,7320
31 Mar 165,637531,7680
31 Dec 155,5294282,8920
30 Sep 155,1662072,9340
30 Jun 154,753-51,5460
31 Mar 154,690-2081,7150
31 Dec 144,624-6152,948103
30 Sep 144,732-4662,906103
30 Jun 144,742-1991,7020
31 Mar 144,737-52,773103
31 Dec 134,545-1652,555164

Des revenus de qualité: ASTRAZEN a un important ponctuel perte de ₹423.4M impactant ses 12 derniers mois de résultats financiers à 30th June, 2024.

Augmentation de la marge bénéficiaire: Les marges bénéficiaires nettes actuelles de ASTRAZEN sont inférieures à celles de l'année dernière ASTRAZEN. (6.9%) sont inférieures à celles de l'année dernière (12.5%).


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: Les bénéfices de ASTRAZEN ont augmenté de 15.2% par an au cours des 5 dernières années.

Accélération de la croissance: ASTRAZEN a connu une croissance négative de ses bénéfices au cours de l'année écoulée, elle ne peut donc pas être comparée à sa moyenne sur 5 ans.

Bénéfices par rapport au secteur d'activité: ASTRAZEN a enregistré une croissance négative de ses bénéfices ( -27.9% ) au cours de l'année écoulée, ce qui rend difficile la comparaison avec la moyenne du secteur Pharmaceuticals ( 19.5% ).


Rendement des fonds propres

ROE élevé: Le retour sur capitaux propres de ASTRAZEN ( 13.5% ) est considéré comme faible.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé